Lenvima^® Used to Treat Endometrial Cancer Added Drug Price Negotiation List

The Trump administration recently released the list of drugs selected for the third cycle of the Medicare Drug Price Negotiation Program. The list includes the drug Lenvima^®, indicated for endometrial cancer. Drugs are chosen for inclusion in the program based on total expenditures payable under Medicare Part B, and under Part D when applicable. Lenvima^®, which is also used to treat thyroid cancer, liver cancer, and kidney cancer in addition to endometrial cancer accounted for approximately $1 billion in Medicare drug spending from November of 2024 to October of 2025, and was prescribed to 10,000 Medicare beneficiaries. The fact sheet that accompanies the list provides additional criteria for inclusion. Negotiated prices for the third round will be applied in the Medicare program in 2028.

Lenvima^®’s selection signals that Medicare reimbursement for this drug will change in 2028, once CMS finalizes a Maximum Fair Price following negotiations in 2026. While nothing changes for prescribing or coverage today, its inclusion on the negotiation list identifies Lenvima^® as one of Medicare’s highest‑spend therapies, which means practices, health systems, and payers should anticipate future adjustments in reimbursement, contracting, and budgeting as CMS releases implementation guidance for Part B drugs. This early notice gives stakeholders time to monitor developments and prepare for financial and operational impacts well ahead of the 2028 effective date.